Q
In patients with previous aspirin-induced ulcer bleeding, is clopidogrel non-inferior to low dose aspirin plus esomeprazole for preventing recurrent ulcer bleeding?
METHODS
Design: randomised placebo controlled trial.
Allocation: concealed.* Blinding: blinded (clinicians, patients, outcome assessors, {data collectors, data analysis, and data safety and monitoring committee}À).* Follow up period: 12 months.
Setting: Prince of Wales Hospital in Hong Kong.
Patients: 320 patients (mean age 72y, 66% men) who had a history of ulcer bleeding and endoscopically confirmed ulcer healing and either tested negative for Helicobacter pylori or had successful eradication of H pylori and required antiplatelet therapy during the trial. Exclusion criteria were concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, anticoagulant agents, or corticosteroids; history of gastric surgery (except patch repair); allergy to aspirin or clopidogrel; presence of erosive oesophagitis, gastric-outlet obstruction, terminal illness, or cancer; or requirement for dialysis.
Intervention: clopidogrel, 75 mg, plus placebo (n = 161) or aspirin, 80 mg, plus esomeprazole, 20 mg (n = 159) twice daily for 12 months.
Outcomes: recurrent ulcer bleeding. Secondary outcomes were lower gastrointestinal bleeding and adverse effects.
Patient follow-up: 99% (intention to treat analysis).
*See glossary.
ÀInformation provided by author.
MAIN RESULTS
More patients in the clopidogrel group than in the aspirin-plusesomeprazole group had recurrent ulcer bleeding (table) . The groups did not differ for lower gastrointestinal bleeding (table). Adverse event rates for clopidogrel and aspirin plus esomeprazole were 1.9% and 0%, respectively, for extragastrointestinal bleeding; 7.5% and 2.5%, respectively, for dyspepsia; 5.6% and 6.9%, respectively, for recurrent ischaemic events; and 1.9% in each group for allergy.
CONCLUSION
In patients with previous aspirin induced ulcer bleeding, the addition of esomeprazole to aspirin was better than changing to clopidogrel for reducing recurrent ulcer bleeding. 
Commentary
T he use of antiplatelet agents (eg, low dose aspirin or clopidogrel) for the prevention of cardiovascular events is widespread. Low dose aspirin is ulcerogenic, so its use alone is contraindicated in patients at high risk of ulcer bleeding. Alternative approaches in such patients include adding a proton-pump inhibitor (PPI) to aspirin 1-2 or using a nonaspirin agent (clopidogrel) instead. The study by Chan et al is the first to directly compare these 2 approaches in patients who have bled once from an aspirin associated ulcer. Somewhat surprisingly, the results of this study clearly show that the second option is not acceptable. Although clopidogrel had been believed to be non-ulcerogenic, it was associated with a substantially higher incidence of recurrent ulcer bleeding than was low dose aspirin plus a PPI (esomeprazole). Because the incidence of adverse events prevented by antiplatelet therapy was similar in the 2 groups, the recommendation to switch patients with a previous aspirin associated bleeding ulcer to clopidogrel alone is not justified. In patients who truly cannot take aspirin, clopidogrel could be used with a concomitant PPI, although this has not yet been proven to be safe.
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